Fuda Cancer Hospital
Sigmoid adenocarcinoma treatment cost in China runs from $16,500 to $24,500 for primary surgical resection. Specialized radiation therapy for colorectal cancer generally ranges from $11,500 to $27,500. Total expenses depend on the cancer stage, technology used, and required adjuvant therapies. Patients can expect 50-70% savings compared to the United States. Top medical hubs include Guangzhou, Beijing, and Shanghai.
Typical Sigmoid Adenocarcinoma Treatment Costs in China
Bookimed Expert Insight: Patients with advanced or complex cases benefit from centers offering multi-modal, minimally invasive therapies. Fuda Cancer Hospital in Guangzhou provides over 10 innovative options, including cryosurgery and NanoKnife. This JCI-accredited facility has treated over 30,000 international patients. For precision radiation, Xiamen Humanity Hospital features specialists like Professor Liu Shi Xin. He excels in VMAT and SBRT for abdominal cancers.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Colectomy (large bowel resection) | from $16,500 | from $6,912 | from $22,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Sigmoid adenocarcinoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Sigmoid adenocarcinoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Sigmoid adenocarcinoma treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
Chinese hospitals treat sigmoid adenocarcinoma using the Chinese Society of Clinical Oncology (CSCO) and National Health Commission (NHC) guidelines. These standards align with international NCCN and ESMO frameworks. They emphasize biomarker-driven therapy and multidisciplinary team (MDT) protocols for complex or metastatic cases.
Bookimed Expert Insight: Data shows Chinese oncology centers like JCI-accredited Fuda Cancer Hospital emphasize specialized minimally invasive therapies for advanced stages. While domestic guidelines recommend standard chemotherapy, these high-volume centers often integrate targeted protocols like NanoKnife or cryosurgery for metastasis. This specialized expertise attract patients from over 100 countries seeking alternatives for late-stage sigmoid cancer.
Patient Consensus: Patients note that major academic hospitals follow international-style protocols, so they recommend seeking opinions from high-volume tertiary centers. They emphasize asking explicitly about lymph node harvest and stoma risks, as these critical details are often discussed very briefly.
Oncologists determine a tumor stage before treatment using clinical staging. This baseline identifies the primary tumor size and its spread through imaging and biopsy. In China, centers like Fuda Cancer Hospital use PET/CT and CT scans for precise visualization. Doctors then apply the TNM framework to categorize the cancer from Stage 0 to IV.
Bookimed Expert Insight: Patient volume often correlates with diagnostic accuracy in Chinese oncology. Fuda Cancer Hospital has served over 30,000 international patients and specializes in advanced-stage cancer. This high volume allows specialists like Dr. Liu Shi Xin to better interpret nuanced imaging scans that standard protocols might miss.
Patient Consensus: Patients note that pre-treatment staging is often an estimate based on imaging. They emphasize asking whether a report reflects clinical or pathologic results, as surgery often reveals microscopic spread missed by CT scans.
Standard minimally invasive options for sigmoid colon cancer in China include laparoscopic and robotic-assisted radical sigmoidectomy. High-volume centers perform these procedures following Chinese Society of Clinical Oncology (CSCO) guidelines. Techniques like Natural Orifice Specimen Extraction are also widely utilized in specialized Chinese oncology departments.
Bookimed Expert Insight: While many focus on robotic technology, the true indicator of quality in China is the surgeon’s volume at JCI-accredited facilities like Fuda Cancer Hospital. This hospital has treated over 30,000 international patients. Clinical success here often depends on specialized minimally invasive therapies that serve as alternatives to traditional systemic chemotherapy.
Patient Consensus: Patients emphasize finding a colorectal specialist who performs these resections daily rather than focusing on the robot brand. They often note that even minimally invasive surgery requires a real recovery period including bowel preparation.
China follows CSCO guidelines for sigmoid adenocarcinoma. First-line regimens consist of CapeOx or FOLFOX for stage II and III. Metastatic cases utilize those backbones plus FOLFIRI or FOLFOXIRI. Biomarker status determines the addition of targeted agents like Cetuximab or Bevacizumab.
Bookimed Expert Insight: Patient volume at specialized centers like Fuda Cancer Hospital creates a high level of protocol standardization. Our data shows oncology patients often choose these JCI-accredited facilities because they provide access to multi-disciplinary teams. These teams combine systemic chemotherapy with advanced technologies like NanoKnife or vascular interventional therapy to manage complex cases.
Patient Consensus: Patients note that choosing between FOLFOX or CapeOx often depends on convenience versus hospital visits. While oral options save time, managing side effects like hand-foot syndrome requires close coordination with medical staff.
Targeted and immune-based treatments for sigmoid adenocarcinoma are widely available in China. Selection depends on molecular profiling of tumor tissue or blood. Doctors use PET/CT and biopsies to identify specific genetic markers like KRAS, NRAS, and MSI status before prescribing these precision therapies.
Bookimed Expert Insight: While many equate JCI accreditation with standard surgical care, in China it often signals access to advanced non-chemo alternatives. Fuda Cancer Hospital in Guangzhou, which holds JCI status, serves over 30,000 international patients. It uniquely combines targeted approaches with microwave hyperthermia and NanoKnife technologies for late-stage cases.
Patient Consensus: Patients emphasize that these treatments are not automatic and require official molecular reports. Many note that immunotherapy is highly effective but only for the specific MSI-high subset.
Traditional Chinese Medicine (TCM) serves as a supportive therapy alongside standard oncology in China. It complements procedures like colectomy and chemotherapy for sigmoid adenocarcinoma. JCI-accredited facilities integrate acupuncture and herbal medicine to alleviate nausea and fatigue. These methods improve recovery but never replace standard surgical or medical protocols.
Bookimed Expert Insight: Analysis of JCI-accredited centers in China, like Fuda Cancer Hospital, reveals a unique approach to late-stage care. These hospitals often house TCM services directly within the oncology department. This structure allows surgeons like Dr. Ma Xiao Ying to monitor liver labs in real time. Patients benefit when herbal treatments are adjusted immediately based on surgical recovery or chemotherapy cycles.
Patient Consensus: Patients emphasize that TCM is most effective for improving appetite and sleep during recovery. They note it is vital to share all herbal supplements with the oncologist to prevent liver complications.